Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) | Delaware | 85-2786970 | | --- | --- | | (State or other juris ...

Earnings Release Delay - Maravai LifeSciences Holdings, Inc. announced a delay in its earnings release and call originally scheduled for February 25, 2025, due to the need for additional time to complete its financial close process[5]. - The company intends to file a Form 12b-25 for late filing with the SEC on or before March 4, 2025, and plans to submit its annual report on Form 10-K for the fiscal year ended December 31, 2024, by March 18, 2025[5]. Preliminary Revenue Results - Preliminary revenue results for the year ended December 31, 2024, were included in the February 2025 Press Release, although specific figures were not disclosed in the provided content[6].

Schedules Conference Call for Thursday, March 20, 2025SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2024, together with other business updates. The company also expects to file its Annual Report on Form 10-K for the year ended December 31, 2024, with the Securities ...

NEW YORK, March 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zl ...

NEW YORK, March 17, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024 and February 24, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2025.So what: If you purchased Maravai securities during ...

NEW YORK, March 17, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces the filing of a securities class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI). This lawsuit, filed on behalf of those who purchased Maravai securities between August 7, 2024, and February 24, 2025, alleges that the company made materially misleading statements and failed to disclose crucial information to investors.The complaint alleges several key issues. Specifically, it claims Maravai ...

NEW YORK, March 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI).Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=136030&fr ...

Core Viewpoint - A class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for alleged violations of federal securities laws, particularly concerning inadequate internal controls and improper revenue recognition [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Maravai made false and misleading statements regarding its financial reporting and failed to maintain adequate internal controls [2]. - Allegations include improper revenue recognition from certain transactions in fiscal 2024 and an overstatement of goodwill [2]. Group 2: Investor Information - Shareholders who purchased Maravai's securities between August 7, 2024, and February 24, 2025, are encouraged to contact the DJS Law Group before May 5, 2025, to participate in the lawsuit [1].

Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial reporting during the Class Period from August 7, 2024, to February 24, 2025 [1][2]. Allegations Against Defendants - The complaint claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is alleged that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The lawsuit states that Maravai's goodwill was overstated, leading to misleading positive statements about the company's business and prospects [2] Lead Plaintiff Process - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [3] - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3] - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3] Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4] - The firm encourages Maravai investors who have suffered losses to contact them for more information [4]

Core Viewpoint - The stock market is experiencing volatility, leading to concerns about the economy, and while buying stocks during downturns can be beneficial for long-term investors, not all struggling stocks will recover. Group 1: SoundHound AI - SoundHound AI has seen its stock price decline over 55% since the beginning of the year after a significant rise of 836% last year, primarily due to Nvidia selling its stake in the company [3][4] - The company reported a revenue increase of 85% to $84.7 million last year, but also posted an adjusted net loss of $69.1 million, which is 19% higher than the previous year, raising questions about its future growth potential [5] - There are concerns regarding SoundHound's ability to compete in a crowded AI market, which may hinder its organic growth despite its current revenue generation [4][5] Group 2: Maravai LifeSciences - Maravai LifeSciences' stock has also dropped around 55% this year, following a surge in demand for its products during the pandemic, particularly for mRNA vaccine development [6] - The company reported a revenue of $202.8 million for the nine months ending September 30, 2024, which is a 6% decrease year over year, alongside an operating loss of $197.5 million, including significant goodwill impairment charges [7] - With uncertain future profitability and a lack of positive indicators, the stock may continue to decline as the year progresses [8] Group 3: Victoria's Secret & Co. - Victoria's Secret has experienced a 59% decline in stock price so far in 2025, attributed to disappointing earnings and a bleak outlook [9] - The company projects sales for the current fiscal year to be between $6.2 billion and $6.3 billion, indicating minimal growth compared to the previous year, where sales were $6.2 billion, reflecting less than 1% growth [10] - Management's optimistic forecast assumes improving economic conditions, which may not materialize, potentially leading to even lower sales figures if the economic environment does not improve [11][12]